PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25583751-0	2015	SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.	telaprevir	123-133	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	0-7	
25583751-2	2015	Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone.	telaprevir	139-149	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	21-28	
25583751-2	2015	Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone.	telaprevir	139-149	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	44-48	
25583751-7	2015	In multivariate analysis, older age (P=0.03), lower baseline Hb concentration (P=0.02) and SLC29A1 rs760370 GG (P=0.02) were associated with the development of severe anaemia during treatment, whereas no association was found with ITPA SNPs in our population receiving telaprevir-based therapy.	telaprevir	269-279	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	91-98	
25583751-8	2015	CONCLUSIONS: In patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin.	telaprevir	60-70	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	112-119